» Articles » PMID: 20398960

Reliability Assessment and Validation of the Melasma Area and Severity Index (MASI) and a New Modified MASI Scoring Method

Overview
Specialty Dermatology
Date 2010 Apr 20
PMID 20398960
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The Melasma Area and Severity Index (MASI), the most commonly used outcome measure for melasma, has not been validated.

Objective: We sought to determine the reliability and validity of the MASI.

Methods: After standardized training, 6 raters independently rated 21 patients with mild to severe melasma once daily over a period of 2 days to determine intrarater and interrater reliability. Validation was performed by comparing the MASI with the melasma severity scale. The darkness component of the MASI was validated by comparing it with the difference between mexameter scores for affected versus adjacent normal-appearing skin. The area component of the MASI was validated by comparing it with the area of each section of the face determined by computer-based measurement software.

Results: The MASI score showed good reliability within and between raters and was found to be valid when compared with the melasma severity scale, mexameter scores, and area measurements. Homogeneity assessment by raters showed the least agreement and can be removed from the MASI score without any loss of reliability.

Limitations: Patients were limited to Hispanic, African, and Asian backgrounds.

Conclusion: The MASI is a reliable measure of melasma severity. Area of involvement and darkness are sufficient for accurate measurement of the severity of melasma and homogeneity can be eliminated.

Citing Articles

Evaluation of the Efficacy of a Serum Containing Niacinamide, Tranexamic Acid, Vitamin C, and Hydroxy Acid Compared to 4% Hydroquinone in the Management of Melasma.

Rocio J, Pittet J, Sachdev M, Kovylkina N, Deloche Bensmaine C, Passeron T J Cosmet Dermatol. 2025; 24(3):e70097.

PMID: 40062688 PMC: 11892338. DOI: 10.1111/jocd.70097.


Association of Genetic Polymorphisms in SLC45A2, TYR, HERC2, and SLC24A in African Women with Melasma: A Pilot Study.

Mpofana N, Mlambo Z, Makgobole M, Dlova N, Naicker T Int J Mol Sci. 2025; 26(3).

PMID: 39940926 PMC: 11818098. DOI: 10.3390/ijms26031158.


Effectiveness and Safety of Combined Use of Home-Based Radiofrequency Device and Arbutin Cream in Melasma and Facial Rejuvenation.

Zhang L, Zhao Q, Che Q, Wang W, Chen T, Tang X J Cosmet Dermatol. 2025; 24(2):e70007.

PMID: 39918262 PMC: 11804296. DOI: 10.1111/jocd.70007.


Amelioration of Melasma Using Quantum Molecular Resonance.

Cho E, Kim M J Cosmet Dermatol. 2024; 24(2):e16701.

PMID: 39648306 PMC: 11845929. DOI: 10.1111/jocd.16701.


Melasma Management: A Comprehensive Review of Treatment Strategies Including BTX-A.

Kania B, Lolis M, Goldberg D J Cosmet Dermatol. 2024; 24(2):e16669.

PMID: 39533523 PMC: 11845932. DOI: 10.1111/jocd.16669.